• Ambe Phytoextracts has undertaken an in vitro anti-viral study against SARS CoV-2 virus, established that Bio-Immune™ inhibited the replication of SARS CoV 2 virus with 99.91% inhibition of SARS CoV-2 virus replication.
• The study was carried out in an ICMR (Indian Council of Medical Research) approved laboratory. Results for the same can be found here.
• The published paper can be accessed by clicking here
SAFETY STUDIES:
Preclinical Studies has proven that Bio-Immune™ to be safe for both Oral & Pulmonary delivery formulation.
| Acute Toxicity Study (Oral Route): | Bio-ImmuneTMat the oral dose equivalent to 2000 mg/kg in rat was found to be safe. LD50 (Lethal dose) was found to be >2000 mg/kg as per the OECD 423 guidelines. |
| Sub-acute Toxicity Study (Oral Route): | Bio-ImmuneTMat the oral dose equivalent to 666 mg/kg in rat was found to be safe. The No observed Adverse Effect Level (NOAEL) of the present subacute oral toxicity study was found to be 666 mg/kg. |
| Acute Toxicity Study (Pulmonary Route): | Dose equivalent to 5 mg/L/4hr in rat was found to be safe. LD50 (Lethal dose) was found to be 5 mg/L/4hr as per the OECD 403 guidelines. |
| Sub-acute Toxicity Study (Pulmonary Route): | Bio-ImmuneTM at the dose equivalent to 0.5 mg/L/4hr/Day in rat was found to be safe. NOAEL was found to be 1/10 of MTC (0.5 mg/L/4hr/Day) and LOAEL. |